Jane Gesemyer, a former realtor from Newtown, PA, was 67 when she got an explanation for her sudden debilitating exhaustion: mantle cell lymphoma. She started chemotherapy, but her cancer resisted treatment. Her doctor then referred her to the Abramson Cancer Center at Penn Medicine for CAR T cell therapy—a treatment option approved by the Food and Drug Administration (FDA) for several forms of leukemia, lymphoma, and myeloma—and first made possible thanks to two decades of research at Penn.
The story behind Gesemyer's treatment exemplifies the virtuous cycle of research—from idea to laboratory science, private industry investment, and back to new cycles of discovery.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
